ForDoz Pharma Corporation
http://www.fordozpharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ForDoz Pharma Corporation
Lupin Expects Respiratory Ramp Up From Fiscal '22
After launching albuterol, India's Lupin is seeking to expand its presence in the respiratory market. With generic Fostair set for a European launch in fiscal 2022 and Spiriva for a US introduction the following fiscal year, the company is counting on the portfolio to deliver growth from the coming financial year.
Lupin Expects Respiratory Ramp Up From Fiscal '22
After launching albuterol, India's Lupin is seeking to expand its presence in the respiratory market. With generic Fostair set for a European launch in fiscal 2022 and Spiriva for a US introduction the following fiscal year, the company is counting on the portfolio to deliver growth from the coming financial year.
Deal Watch: NewAmsterdam To Take On Amgen’s Stalled CETP Inhibitor
New company licenses obicetrapib from Amgen after previous companies’ setbacks in CETP class and works with FDA on a Phase III protocol. BMS buys protein-engineering specialist Forbius.
Company Information
- Industry
- Biotechnology
- Contract Research, Toxicology Testing-CRO
- Pharmaceuticals
- Contract Manufacturing Organization
-
Pharmaceuticals
- Specialty Pharmaceuticals